Human urothelial carcinoma cell response to Sunitinib malate therapy in vitro

Cancer Cell International

Volumn 15, Issue 1, 2015, Pages

  Wen, Jin ^a   Li, Han Zhong ^a   Ji, Zhi Gang ^a   Jin, Jing ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Bladder cancer; Cisplatin; Proliferation; Sorafenib; Sunitinib

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4',6 DIAMIDINO 2 PHENYLINDOLE; CISPLATIN; SORAFENIB; SUNITINIB;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER CELL LINE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MTT ASSAY; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING;

EID: 84928723986     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-015-0179-z     Document Type: Article

References (12)

1. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12:107-13
2. Roskoski Jr R. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007;356:323-8
3. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-24
4. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwits HI, Eckhardt SG, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007;25:4793-9
5. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:650-6
6. Yoon CY, Lee JS, Kim BS, Jeong SJ, Hong SK, Byun SS, et al. Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells. Korean J Urol. 2011;52:55-63
7. Silay MS, Miroglu C. Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their antiangiogenic effects. Hypotheses. 2007;69:892-5
8. Droller MJ. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. J Urol. 1998;160:1932
9. Chabannes E, Bernardini S, Wallerand H, Bittard H. Angiogenesis in bladder: prognosis indicator and therapeutic target. Prog Urol. 2001;11:417-27
10. Szarvas T, Jäger T, Droste F, Becker M, Kovalszky I, Romics I, et al. Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathol Oncol Res. 2009;15:193-201
11. Liu L, Zhu D, Gao R, Guo H. Expression of vascular endothelial growth factor, receptor KDR, and p53 protein in transitional cell carcinoma of the bladder. Urol Int. 2008;81:72-6
12. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26:1810-6